Home Cart Sign in  
Chemical Structure| 118292-40-3 Chemical Structure| 118292-40-3

Structure of Tazarotene
CAS No.: 118292-40-3

Chemical Structure| 118292-40-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Tazarotene selectively binds to retinoic acid receptors RAR-β and RAR-γ, it is the first receptor-selective aromatic retinoid that has effective treatment for psoriasis, hemorrhoids.

Synonyms: AGN 190168

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Tazarotene

CAS No. :118292-40-3
Formula : C21H21NO2S
M.W : 351.46
SMILES Code : O=C(C1=CC=C(C#CC2=CC=C3C(C(C)(C)CCS3)=C2)N=C1)OCC
Synonyms :
AGN 190168
MDL No. :MFCD00867628
InChI Key :OGQICQVSFDPSEI-UHFFFAOYSA-N
Pubchem ID :5381

Safety of Tazarotene

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Porcine skin 0.4–18,750 ng/mL 16 hours Developed and validated an ultra-performance liquid chromatography with quadrupole detector mass spectrometry (UPLC-QDa) method for the simultaneous quantification of tazarotene and its active metabolite tazarotenic acid in porcine skin. The method demonstrated linearity over the range of 0.4–18,750 ng/mL with r²≥0.99, and met FDA guidelines for accuracy and precision. Int J Mol Sci. 2025 Jan 9;26(2):489.
MSDi cells 10 µM 3 and 6 days Analysis of ARSA and GALNS activities, only Tazarotene significantly increased activity EMBO Mol Med. 2023 Mar 8;15(3):e14837.
MSDi cells 2 µM to 50 µM 3 days Dose-dependent significant increase in ARSA activity, EC50 4.9 µM EMBO Mol Med. 2023 Mar 8;15(3):e14837.
MSDi cells 10 µM 48 hours Recovery of arylsulfatase A activity served as the primary readout. EMBO Mol Med. 2023 Mar 8;15(3):e14837.
Human dermal fibroblasts (HDF) 7 µM 7 days Promotes angiogenesis in endothelial cell-fibroblast coculture Mol Ther. 2016 Oct;24(10):1745-1759.
MSDi cells 10 µM 72 hours Increased ARSA activity via RAR receptors, RAR antagonist AGN193109 could block this effect EMBO Mol Med. 2023 Mar 8;15(3):e14837.
Human umbilical vein endothelial cells (HUVEC) 10 µM 8 hours Promotes endothelial tube formation and branching morphogenesis Mol Ther. 2016 Oct;24(10):1745-1759.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL mice Diabetic mouse model Transdermal delivery 1 mg/10 ml Continuous release Promote diabetic wound healing J Nanobiotechnology. 2022 Mar 19;20(1):147
Mice Matrigel implant and ear punch wound healing model Intraperitoneal injection 10 mg/kg Daily for 6 days Enhances growth of functional microvessels and wound healing Mol Ther. 2016 Oct;24(10):1745-1759.

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00779896 Cutaneous T-Cell Lymphoma PHASE1|PHASE2 UNKNOWN 2025-12-12 McGill University, Montreal, Q... More >>uebec, H2W 1S6, Canada Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.85mL

0.57mL

0.28mL

14.23mL

2.85mL

1.42mL

28.45mL

5.69mL

2.85mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories